Do ICS/LABA fixed combinations provide superior asthma control compared to separate inhalers?

Peter J Barnes; Gabriele Nicolini; Andrea Bizzi; Dave Singh

doi:10.7490/f1000research.594.1

Related publications

Article2012

Do inhaled corticosteroid/long-acting beta<sub>2</sub>-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal

Peter J Barnes, Gabriele Nicolini, Andrea Bizzi, Monica Spinola, Dave Singh

Article2010

Fluticasone Furoate, A Novel Enhanced-affinity Inhaled Corticosteroid (ICS), Has Superior Anti-inflammatory Effects Compared To Fluticasone Propionate Under Conditions Of Oxidative Stress

Christos Rossios, Yasuo To, Misako Ito, Peter J Barnes, Ian M. Adcock, Malcolm Johnson, Kazuhiro Ito

Article2024

A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy

Mark L Levy, Richard Beasley, Bev Bostock, Toby Capstick, Michael G. Crooks, Louise Fleming, Daryl Freeman, Viv Marsh, Hitasha Rupani, Andy Whittamore, Peter J Barnes, Andrew Bush

Article2008

Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled β 2 -Agonists in Achieving Asthma Control

Paul M. O’Byrne, Ian Naya, Anders Källén, Dirkje S. Postma, Peter J Barnes

Article2021

Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine

Maria Gavriatopoulou, Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Αlexandros Briasoulis, Sentiljana Gumeni, Despina Fotiou, Eleni‐Dimitra Papanagnou, Magdalini Migkou, Foteini Theodorakakou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstathios Kastritis, Meletios A Dimopoulos